Tempus

Tempus Acquires Personalis for $1.5 Billion, Bolstering Position in Blood-Based Cancer Diagnostics

Tempus's $1.5 billion acquisition of Personalis significantly strengthens its foothold in the rapidly expanding blood-based cancer diagnostics market. This strategic move reflects growing medtech interest in less invasive testing, impacting procurement strategies, regulatory pathways, and competitive dynamics across the global oncology sector. Decision-makers must assess portfolio shifts and supply chain implications.